Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Fuji
Federal Trade Commission
Healthtrust
Baxter
US Department of Justice
Queensland Health
Express Scripts
Cantor Fitzgerald

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,349,840

« Back to Dashboard

Which drugs does patent 8,349,840 protect, and when does it expire?

Patent 8,349,840 protects REXULTI and is included in one NDA.

This patent has twenty-six patent family members in twenty-five countries.
Summary for Patent: 8,349,840
Title:Piperazine-substituted benzothiophenes for treatment of mental disorders
Abstract: The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety. ##STR00001##
Inventor(s): Yamashita; Hiroshi (Tokushima, JP), Ito; Nobuaki (Tokushima, JP), Miyamura; Shin (Tokushima, JP), Oshima; Kunio (Tokushima, JP), Matsubara; Jun (Tokushima, JP), Kuroda; Hideaki (Tokushima, JP), Takahashi; Haruka (Tokushima, JP), Shimizu; Satoshi (Tokushima, JP), Tanaka; Tatsuyoshi (Tokushima, JP)
Assignee: Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:12/970,690
Patent Claim Types:
see list of patent claims
Composition; Compound; Use;

Drugs Protected by US Patent 8,349,840

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Otsuka Pharm Co Ltd REXULTI brexpiprazole TABLET;ORAL 205422-001 Jul 10, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Sign Up
Otsuka Pharm Co Ltd REXULTI brexpiprazole TABLET;ORAL 205422-002 Jul 10, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Sign Up
Otsuka Pharm Co Ltd REXULTI brexpiprazole TABLET;ORAL 205422-003 Jul 10, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Sign Up
Otsuka Pharm Co Ltd REXULTI brexpiprazole TABLET;ORAL 205422-004 Jul 10, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,349,840

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2005-116698Apr 14, 2005

Non-Orange Book US Patents Family Members for Patent 8,349,840

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,206,167 Piperazine-substituted benzothiophenes for treatment of mental disorders ➤ Sign Up
7,888,362 Piperazine-substituted benzothiophenes for treatment of mental disorders ➤ Sign Up
9,839,637 Piperazine-substituted benzothiophenes for treatment of mental disorders ➤ Sign Up
9,480,686 Piperazine-substituted benzothiophenes for treatment of mental disorders ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Teva
Healthtrust
Baxter
US Army
Cipla
Julphar
Cerilliant
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.